Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

: Phosphate is a macro-element involved in all cellular energetic processes. As about 90% of the phosphate filtered by the glomerulus is excreted by kidneys, the impairment of renal function and the consequent over-secretion of parathyroid hormone and fibroblast growth factor 23 results in the increase in the serum phosphate levels. The association between phosphate and hemoglobin is controversial, as both direct and indirect relationships have been reported. The present study aims to investigate the relationship between phosphate and hemoglobin in a large prospective, longitudinal cohort including dialysis patients from the Sicilian Registry of Nephrology, Dialysis, and Transplantation. : In this prospective cohort study, we included 6263 hemodialysis patients to achieve a total of 120,462 repeated measurements of serum phosphate and hemoglobin over time. The longitudinal association between phosphate and hemoglobin was analyzed by univariate and multivariate Linear Mixed Models. The mean age was 66 ± 16 years and the median dialysis vintage was 5 months [IQR: 2-16]. Mean and median values of hemoglobin and phosphate were 10.7 g/dL (SD 1.3 g/dL) and 4.6 mg/dL [IQR 3.9-5.5 mg/dL], respectively. The multivariate model, adjusted for potential confounders, confirmed the positive association between serum phosphate and hemoglobin [adjβ = 0.13, 95%CI 0.03-0.23, = 0.01)]. These results were confirmed in analyses stratified for the use of phosphate binders. In our large cohort of dialysis patients, we found a linear, direct relationship between phosphate and hemoglobin levels. As a reduction in phosphate is associated with a parallel reduction in hemoglobin levels, hypophosphatemia can accentuate anemia in dialysis patients. Our results generate the hypothesis that monitoring serum phosphate in clinical practice might provide a better management of anemia.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11477030PMC
http://dx.doi.org/10.3390/jcm13195657DOI Listing

Publication Analysis

Top Keywords

phosphate hemoglobin
28
serum phosphate
20
dialysis patients
16
phosphate
14
hemoglobin
9
large cohort
8
cohort dialysis
8
association phosphate
8
relationship phosphate
8
hemoglobin levels
8

Similar Publications

Caffeine is the most widely consumed psychoactive substance globally, yet its peripheral physiological effects remain incompletely understood. Leveraging comprehensive data from 13,091 blood donors in the REDS RBC-Omics study, we identify caffeine as a significant modulator of red blood cell (RBC) storage quality and transfusion outcomes. Elevated caffeine levels were reproducible across multiple donations from 643 recalled donors, selected based on their extremes in hemolytic propensity.

View Article and Find Full Text PDF

Background: Elevated serum phosphate levels are strongly associated with an increased risk of all-cause mortality in patients with chronic kidney disease (CKD). The aim of this study was to identify independent risk factors for hyperphosphatemia in patients with non-dialysis CKD and use the findings to develop and validate a predictive model for assessing hyperphosphatemia risk.

Methods: Data of patients with CKD discharged from the Department of Nephrology between January 2021 and December 2023 were retrospectively analyzed.

View Article and Find Full Text PDF

Background: End-stage kidney disease (ESKD) requires lifelong kidney replacement therapy (KRT), which significantly influences patients' quality of life (QoL). Primary KRT modalities include hemodialysis (HD), peritoneal dialysis (PD), and kidney transplant (KTX), each with varying impacts on QoL and clinical outcomes. Comparative data regarding these modalities in the local context, is limited.

View Article and Find Full Text PDF

Blood tests are widely used to assess a patient's health status. Microfluidics, in combination with electrochemical impedance spectroscopy (MEIS), opens up great prospects for blood analysis. This study aimed to improve the MEIS blood tests.

View Article and Find Full Text PDF

Background: Uncontrolled type 2 diabetes mellitus warrant the utilization of different combination antidiabetic therapies, however, the addition of these newer agents as add-on therapy increases the risk of side effects and needs to be further investigated in terms of their risk to benefit to the patient. Therefore, the current study aims to evaluate the clinical and safety outcomes in patients taking empagliflozin and Sitagliptin in addition to metformin.

Method: A cross-sectional study was conducted using a non-probability consecutive sampling technique to gather data at the Diabetes and Foot Care Clinic in Abbottabad from July 2023 to December 2023.

View Article and Find Full Text PDF